Does Omega-3 Dry Eye Randomized Trial work?

The current Migaku evidence database contains 2 reusable source documents for Omega-3 Dry Eye Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Between-group comparisons revealed significantly higher improvements in the BLT group: Schirmer's test (Schirmer I) improved by MD = 8.7 (95% CI: 7.64-9.76; p = 0.001), TBUT by MD = 2.97 (95% CI: 1.7-4.3; p = 0.007), and DEQS decreased by MD = - 24.1 (95% CI: -37 to - 17.1; p = 0.002). [Mohamed Elsayed Saad E (2026); evidence level 2] - To examine the short-term therapeutic effects of Bioptron light therapy (BLT) on dry eye disease (DED) in postmenopausal women. [Mohamed Elsayed Saad E (2026); evidence level 2] - Sixty postmenopausal women diagnosed with DED, aged 50-62 years with a body mass index ≤ 30 kg/m², were randomly assigned to two equal groups. [Mohamed Elsayed Saad E (2026); evidence level 2] - It is also believed that the risk increases with age but there are more and more cases of the disease among 18–50-year-old age groups because of commonly worn contact lenses and worldwide-used electronic devices like smartphones or computers []. [Pniakowska Zofia (2026); evidence level 3] - This process is accompanied by symptoms reported by patients, and its development is associated with tear film instability, increased osmolarity, inflammatory response, and damage to the barrier of the ocular surface. [Pniakowska Zofia (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.